dsip portfolio managed 2 Discovery of first-in-class inhibitors of the TRF1:TIN2 protein:protein interaction by fragment screening Quantity:60 𝗕𝗣𝗖-𝟭𝟱𝟳 Healing Joint Cream, vegetable capsule – Quantity:1 Vial retatrutide/cagrilintide blend Retatrutide + HARDCORE SERIES

dsip portfolio managed 2 Discovery of first-in-class inhibitors of the TRF1:TIN2 protein:protein interaction by fragment screening Quantity:60 𝗕𝗣𝗖-𝟭𝟱𝟳 Healing Joint Cream, vegetable capsule – Quantity:1 Vial retatrutide/cagrilintide blend Retatrutide + HARDCORE SERIES

retatrutide/cagrilintide blend Retatrutide + Cagrilintide Combo Vincent Pedre, MD FMCP Peptide Injection Specification:20 mg vial –

Sustained Weight Loss and Prevention of Weight Regain One significant advantage of using semaglutide B12 compounds is the potential for sustained weight loss

HARDCORE SERIES

Quantity:1 Vial

PE-22-28 Safety Considerations# PE-22-28's safety profile is less burdened by mechanism-specific concerns: TREK-1 channels are expressed throughout the body (brain, heart, vasculature, gastrointestinal tract), so systemic TREK-1 blockade could theoretically affect cardiovascular function, pain sensation, and gastrointestinal motility